Navigation Links
Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
Date:11/27/2007

BRISBANE, Australia, Nov. 27 /PRNewswire/ -- Xenome Ltd., a leader in developing unique peptides for therapeutic applications in a variety of diseases, today announced the signing of a joint research collaboration agreement with Amylin Pharmaceuticals, Inc. The partnership will focus on the discovery and development of novel peptide therapeutics for a range of metabolic and musculoskeletal diseases.

In addition to the joint research collaboration agreement, Amylin has made an equity investment in Xenome matched by investments from Queensland BioCapital Funds and Innovis Australia.

Under the collaboration, Amylin will apply its proprietary screening technologies to evaluate the therapeutic potential of the peptides from Xenome's proprietary bioactive peptide library derived from natural sources. Amylin will have the right to select and exclusively license lead candidates resulting from a screening program in metabolic and musculoskeletal disease for further development and commercialization in exchange for milestone payments and royalties payable to Xenome.

"This collaboration with Amylin is an important strategic move for Xenome as it provides us with funding, and the ability to leverage our peptide chemistry capabilities in a therapeutic area outside of Xenome's current focus." commented Xenome's CEO Lewis Lee. "Amylin's research organization has successfully created several peptide therapies for the treatment of diabetes and potentially obesity."

"We are pleased to be working with Xenome," said Michael Hanley, Ph.D., Vice President, Discovery Research at Amylin. "Amylin is committed to bringing innovative medicines with life-changing therapeutic potential to patients. This mutually beneficial collaboration combines Xenome's proprietary peptide library with Amylin's therapeutic expertise and creates valuable opportunities to discover and develop novel therapeutics."

To date, Xenome's focus has been in the discovery and development of novel leads for the treatment of pain and inflammatory conditions. Xenome's most advanced clinical product, Xen2174, is currently in a Phase 1b/2a clinical trial for treatment of cancer pain. This clinical trial is near finalization and the interim results are encouraging, providing the Company the confidence to initiate a Phase 2b clinical program in 2008.

Xenome has generated a peptide database, containing over 8,000 peptides from natural sources. From this collection Xenome has synthesized and characterized over 2500 individual peptides to generate a novel library for new drug discovery. This library complements additional peptide libraries at Xenome comprised of other novel peptide analogues.

Further information:

Lewis Lee

Director & CEO

Xenome Ltd

Tel: +61 7 3720 8055

E-mail: lewis.lee@xenome.com

Website: http://www.xenome.com

About Xenome

Xenome is a biotechnology company based in Brisbane Australia with a promising and distinctive technology platform targeting pain and inflammation. Xen2174, the Company's lead product candidate is near completion of a Phase 1b/2a clinical trial for cancer pain. Evidence to date strongly indicates a successful completion to this clinical trial and more substantive clinical trials are planned for 2008. Xenome has generated a unique expertise in peptide chemistry that can translate peptides from natural sources into highly bioactive libraries of molecules that are of interest to global biotechnology and pharmaceutical companies.


'/>"/>
SOURCE Xenome
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
2. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
3. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
4. Navitas Opens New Cancer Rehabilitation Center in Albuquerque in Conjunction With New Mexico Cancer Centers
5. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
6. Service-to-Sales Transformation at Contact Centers Hinges on Soft Skills
7. The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers
8. Community Health Centers Reveal Specific Ramifications of The Medicaid Citizenship and Identification Documentation Requirements
9. Commercial Insurers Reimbursement Rate to New Yorks Community Health Centers Jeopardizes Care
10. Pennsylvania Trauma Systems Foundation Accreditation Status for Trauma Centers
11. Vangent, Inc. Wins Spot on Centers for Medicare & Medicaid Services Enterprise System Development Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 2017 , ... Bio-Optronics Inc. is proud to announce the ... to seamlessly integrate and streamline the way researchers prepare and conduct patient visits. ... and improving efficiency significantly for users – a first in the CTMS industry. ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... Students interested ... Tissue Donation Awareness Scholarship competition., The winner will earn a $1,000 scholarship and have ... competition begins Feb. 1, and the deadline is May 31, with the winner announced ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... privacy panel system. , The Tranquility privacy panel system was designed to ... environment. Tranquility panels help reduce noise and provide the visual privacy required to ...
(Date:1/19/2017)... ... January 19, 2017 , ... Allegheny Health Network (AHN) ... who seek access to the Network’s programs and services in the greater Pittsburgh region. ... care appointments will be offered one for that same afternoon. , AHN ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree Brady ... services to communities throughout eastern Georgia, is embarking on a charity effort to ... disease kills more Americans every year than anything else, yet risk factors associated ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... RATON, Fla. , Jan. 19, 2017 /PRNewswire/ ... a medical device company specializing in the treatment ... such as keloids, with superficial radiation therapy, today ... and full year 2016 financial results on Thursday, February ... The Company will hold a conference call with ...
(Date:1/19/2017)... CAMBRIDGE, England , January 19, 2017 ... MedImmune and Otsuka in the Milner Therapeutics Consortium   ... academic scientists in Cambridge   ... Inc. (NYSE: PFE ) as a partner ... join the Consortium, which enables the efficient transfer of ...
(Date:1/19/2017)... , January 18, 2017 , , Marks E-QURE ... distribution agreement, following similar agreements in ... Wound care is $2 5 ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment ... - Médica Equipos Médicos S.A.S. (TeckMedica) in Colombia for ...
Breaking Medicine Technology: